Your institution may have access to this item. Find your institution then sign in to continue.
Title
Molecular diagnostics.
Abstract
The article reports on the acquisition of Digene Corp. by Dutch diagnostics maker Qiagen. The author notes that a screen for the 13 high-risk types of human papillomavirus (HPV) linked to 70% of cervical cancers is the primary product of Digene. The expected pre-tax cost savings of Quagen is $35-45m per year.